Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

Abstract Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify tho...

Full description

Saved in:
Bibliographic Details
Main Authors: Shiliang Huang, Joel E. Michalek, David A. Reardon, Patrick Y. Wen, John R. Floyd, Peter T. Fox, Geoffrey D. Clarke, Paul A. Jerabek, Kathleen M. Schmainda, Mark Muzi, Hyewon Hyun, Eudocia Quant Lee, Andrew J. Brenner
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/deb48a83797b4c008592d78912bc5b5d
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/deb48a83797b4c008592d78912bc5b5d

Similar Items